NCT03483012: Atezolizumab + Stereotactic Radiosurgery in Triple-negative Breast Cancer and Brain Metastasis

NCT03483012
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Known leptomeningeal or brainstem metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03483012

Comments are closed.

Up ↑